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ABSTRACT
Objectives To establish what proportion of patients 
completing a UK pulmonary rehabilitation (PR) programme 
meet the 2018 National Institute for Health and Care 
Excellence (NICE) chronic obstructive pulmonary disease 
(COPD) guideline (NG115) criteria to have a respiratory 
review to establish whether referral to a lung volume 
reduction multidisciplinary team would be appropriate. 
This respiratory review would include evaluation of 
the presence of hyperinflation and the presence of 
emphysema on CT scan. The NICE criteria include 
measures of breathlessness and exercise capacity but 
these parameters are not completely defined.
Design Observational study.
Setting PR programmes across the UK in 2015 (210 
centres) and 2017 (184 centres) entering data into the 
Royal College of Physicians’ National Asthma and COPD 
Audit Programme.
Participants 8295 (55.7%) of 14 889 patients in 
programmes using incremental shuttle walk test (ISWT) 
or 6- minute walk test (6MWT) as an outcome measure 
completed PR, and 4856 (32.6%) had complete data 
recorded (6MWT/ISWT, baseline spirometry, Medical 
Research Council (MRC) dyspnoea score).
Results Depending on the walking test safety threshold 
adopted for the ISWT (≥140 m or ≥ 80 m) and the MRC 
dyspnoea score threshold used (MRC score ≥3 or ≥4 at the 
end of PR), between 4.9% and 18.1% of PR completers 
met the NICE criteria for a lung volume reduction- focused 
respiratory review.
Conclusions Lung volume reduction therapies are 
beneficial in appropriately selected patients with COPD, but 
few procedures are performed, and treatment pathways 
are unclear. These data help to inform the feasibility of the 
approach recommended by NICE and highlight the need 
for future systematic pathways to reduce inequalities in 
patients being considered for effective treatments.
BACKGROUND
Chronic obstructive pulmonary disease 
(COPD) is a progressive lung disorder where 
lung hyperinflation can cause respiratory 
muscle dysfunction and debilitating breath-
lessness associated with reduced exercise 
tolerance, poor quality of life and reduced 
life expectancy.1–4 Treatment options for 
this group of patients are limited, and often 
individuals remain severely burdened by 
their symptoms despite optimal pharma-
cological therapy and pulmonary reha-
bilitation.5 6 Alongside smoking cessation 
and oxygen therapy, lung volume reduc-
tion (LVR) therapies exist as one of a small 
number of disease- modifying treatments in 
COPD care.7–10
LVR procedures (surgery or endobron-
chial valve placement) have been shown to 
improve dyspnoea, lung mechanics, exercise 
capacity, quality of life and survival in appro-
priately selected patients with COPD.11–15 
Unfortunately, there has been an absence 
of formal referral pathways,16 leading to a 
substantial disparity between the number of 
people likely to benefit and the number of 
procedures performed.16–19
Strengths and limitations of this study
 ► The data analysed in this trial are from a national 
audit, which increases the generalisability of the 
findings.
 ► The study examines the impact of using differ-
ent thresholds in the implementation of National 
Institute for Health and Care Excellence guidance to 
develop systematic pathways to lung volume reduc-
tion procedures.
 ► Due to the high rate of non- completion of pulmonary 
rehabilitation programmes, there are substantial 
missing data at discharge.
 ► This study does not consider patient preferences for 
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Recent UK National Institute for Healthcare Excel-
lence (NICE) guidance (NG115) recommends referral of 
patients with COPD for a specialist LVR respiratory review 
to determine the potential eligibility for LVR: if they have 
a forced expiratory volume in 1 s (FEV1) <50%, do not 
smoke, have a 6- minute walk test (6MWT) of ≥140 m and 
have breathlessness affecting quality of life.7 This assess-
ment should ideally be undertaken after the completion 
of pulmonary rehabilitation (PR) which will be a point at 
which the patient’s functional capacity and management 
of breathlessness should have been optimised. At this LVR 
respiratory review, subsequent to PR and depending on 
the presence of hyperinflation, an appropriate pattern of 
emphysema on CT and the absence of contraindications 
(FEV1 and carbon monoxide transfer factor <20%, signif-
icant pulmonary fibrosis, major comorbidity limiting 
survival), referral to an LVR multidisciplinary team 
(MDT) to consider technical suitability for LVR is recom-
mended. The NICE recommendation therefore sets out a 
three- step process (figure 1).
Some questions remain about the NICE criteria. First, 
the level of breathlessness to trigger consideration of 
possible LVR is not precisely defined, but typically would 
be significant self- reported breathlessness (Medical 
Research Council (MRC) dyspnoea score of ≥4) that the 
patient regards as imposing sufficient lifestyle restriction 
and symptom burden to warrant consideration of an LVR 
procedure. However, disability may deteriorate further in 
the time taken between referral, assessment and investiga-
tion at a specialist centre. It may therefore be more appro-
priate to consider a lower MRC dyspnoea score threshold 
for initial LVR consideration. Second, the NICE COPD 
guideline does not provide a safety threshold if the incre-
mental shuttle walk test (ISWT), which is also frequently 
used to assess exercise capacity at the end of PR,20 is avail-
able rather than the 6MWT.
The primary aim of this study was to assess the propor-
tion of patients with COPD who were appropriate to have 
an LVR respiratory review (CT scan and full lung func-
tion tests) for possible LVR MDT referral at the time of 
completion of PR and how this varied according to the 
criteria used to better understand the practicalities of 
implementing NICE recommendations.
METHODS
We pooled data from all patients completing PR, recorded 
in the UK National Asthma and COPD Audit Programme 
(NACAP)10 in 2015 (n=7413) or 2017 (n=7476) (table 1). 
Based on NICE guideline (NG115) recommendations, 
we first investigated what proportion would be eligible if 
criteria included patients with an MRC dyspnoea score 
≥4, FEV1 <50% predicted, and a 6MWT or ISWT of 
≥140 m, who were not current smokers. In the absence 
of an agreed LVR safety threshold for ISWT, we used (1) 
≥140 m based on the same distance as the 6MWT and (2) 
≥80 m based on the equivalent 6MWT and ISWT thresh-
olds in the multidimensional BODE/iBODE prognostic 
indices, respectively.21 We then relaxed the criteria and 
looked at the same variables but including all with MRC 
dyspnoea score ≥3.
Patient and public involvement
The focus of this research was developed following 
thematic analysis of patient focus groups conducted in 
Figure 1 Three- step pathway for LVR procedures as set out in NICE COPD guideline update 2018 (https://www.nice.org.uk/
guidance/ng115).7 Depending on local arrangements, steps 2 and 3 may be more or less integrated. Contraindications to LVR 
include significant pulmonary fibrosis or major bronchiectasis. COPD, chronic obstructive pulmonary disease; LVR, lung volume 
reduction; MDT, multidisciplinary team including expert input from radiology, respiratory physician and thoracic surgery; NICE, 
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2016.22 Patients and public were not involved directly in 
the design and execution of this analysis of data from the 
UK NACAP PR audit.10 Ethical approval was not required 
for this specific analysis as patient consent was obtained 
at the time of original data collection. The data set was 
anonymised prior to being provided to the research team.
RESULTS
In all, 8295 (55.7%) of 14 889 patients (table 1) in programmes 
using ISWT or 6MWT as an outcome measure completed 
PR, and 4856 (32.6%) had complete data recorded (6MWT/
ISWT, baseline spirometry, MRC dyspnoea score). Of those 
who completed PR with all required data recorded, 238 
(4.9%) were eligible for LVR assessment, based on NICE 
criteria with an MRC dyspnoea score ≥4 (figure 2). This esti-
mate used the same numerical threshold for the ISWT as 
the 6MWT (≥140 m). Using instead the equivalent iBODE 
score criterion (≥80 m) for ISWT cut- off, we found that up to 
310 patients (6.4%) were eligible. If the criteria were relaxed 
to include MRC dyspnoea score ≥3, 763 (15.7%) would be 
eligible based on an ISWT of ≥140 m or 881 (18.1%) based 
on an ISWT of ≥80 m.
Table 1 Pulmonary rehabilitation participant characteristics
n (%) 2015 (n=7413) 2017 (n=7476)
2015 and 2017 
combined 
(n=14 899)
Age (years) 14 886 (99.9) 69 (9.5) 69 (9.3) 69 (9.4)
Sex (female), n (%) 14 889 (100) 3465 (46.7) 3548 (47.5) 7013 (47.1)
Ethnicity (white British), n (%) 13 857 (93.0) 6523 (88.0) 6443 (86.2) 12 966 (87.1)
Smoking status, n (%)
Ex- smoker/never smoked
14 478 (97.2) 5628 (75.9) 5614 (75.1) 11 242 (75.5)
BMI (kg/m2) 9907 (66.5) 27.5 (6.6) 27.9 (6.7) 27.7 (6.6)
Oxygen therapy, n (%)
Prescribed oxygen
14 883 (99.9) 723 (9.8) 513 (6.6) 1236 (8.3)
Referral method, n (%) 14 889 (100)
  GP/practice team 3810 (51.4) 3788 (50.7) 7598 (51.0)
  Hospital consultant 1521 (20.5) 1498 (20.0) 3019 (20.3)
  Community services 903 (12.2) 1120 (15.0) 2023 (13.6)
  Hospital specialist/COPD team 841 (10.6) 636 (8.5) 1477 (9.9)
  Specified post- AECOPD early PR pathway 174 (2.3) 219 (2.9) 393 (2.6)
  Other 219 (3.0) 215 (2.9) 434 (2.9)
FEV1 (L) 8943 (60.0) 1.38 (0.60) 1.42 (0.63) 1.40 (0.62)
FEV1 (% predicted) 8943 (60.0) 55.1 (20.0) 55.7 (20.0) 55.4 (19.9)
ISWT (m) 4666 (31.3) 270.8 (153.1) 276 (152.4) 273 (152.6)
6MWT (m) 3740 (25.1) 324.1 (133.3) 314.6 (115.1) 319 (123.9)
MRC dyspnoea score at assessment, n (%) 13 567 (91.1)
  Grade 1 115 (1.7) 127 (1.9) 242 (1.8)
  Grade 2 1080 (15.8) 1071 (15.8) 2151 (15.9)
  Grade 3 2656 (39.0) 2648 (39.3) 5304 (39.1)
  Grade 4 2328 (34.1) 2301 (34.1) 4629 (34.1)
  Grade 5 643 (9.4) 598 (8.9) 1241 (9.1)
MRC dyspnoea score at discharge, n (%) 6831 (45.8)
  Grade 1 177 (5.3) 225 (6.5) 402 (5.9)
  Grade 2 1020 (30.5) 1061 (30.5) 2081 (30.5)
  Grade 3 1345 (40.2) 1430 (41.0) 2775 (40.6
  Grade 4 671 (20.0) 668 (19.2) 1339 (19.6)
  Grade 5 134 (4.0) 100 (2.8) 234 (3.4)
  SGRQ total score 514 (3.5) 49.9 (16.6) 48.9 (17.3) 49.4 (17.0)
  CAT score 5495 (36.9) 19.9 (7.9) 18.6 (7.8) 19.3 (7.9)
AECOPD, acute exacerbation of chronic obstructive pulmonary disease; BMI, body mass index; CAT, COPD assessment test; COPD, chronic 
obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; GP, general practitioner; ISWT, incremental shuttle walk test; MRC, Medical 
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DISCUSSION
These data indicate that between 4.9% and 18.1% of 
people with COPD completing PR may be eligible for an 
LVR respiratory review to consider onward referral to an 
LVR MDT. This proportion varies mainly according to 
the threshold MRC dyspnoea score set for breathlessness 
and, to a lesser extent, depending on what ISWT distance 
is chosen to match the NICE recommendation to include 
a 6MWT of ≥140 m as a safety criterion. The proportion of 
individuals who fail to complete PR suggests that careful 
consideration should be given as to whether PR discharge 
is the most suitable or only time point for assessing eligi-
bility for LVR.
As this study used data from a national audit, these 
findings can be assumed to be representative of the UK 
population and therefore provide a reasonable estima-
tion of the proportion of patients who may be eligible 
for consideration. However, it is important to note that 
other factors that might influence decision- making such 
as the presence of comorbidities and of course patient 
preference were not recorded. Not all these individuals 
would be suitable for an LVR respiratory review, and only 
a proportion of these would be likely to be referred to an 
LVR MDT. The data do suggest that a systematic approach 
could significantly reduce current inequalities in access 
to this form of treatment.16–18
Current NICE guidance proposes that patients should 
be considered for LVR referral on completion of a PR 
programme, as following this intervention patients should 
be optimised. A failure to complete PR is associated with 
worse long- term outcomes20 23 and could be taken as a 
marker that an individual’s ability to cope with LVR 
surgery is reduced. However, access to PR is limited,6 24 and 
non- completion is common, approximately 38% between 
assessment and completion in NACAP data, which may 
be due to issues unrelated to individual fitness such as 
transport or location of programmes. Patients with more 
severe breathlessness who may derive more symptomatic 
benefit from LVR may be more likely to drop out24 or may 
not be able to train at sufficient intensities to bring about 
improvement through PR and therefore may find the 
exercise very uncomfortable.25 Beginning consideration 
for possible LVR referral at PR assessment may help to 
promote programme adherence and affords the oppor-
tunity to gather other data on comorbidities and previous 
investigations which may be relevant.
In 2017, we published a qualitative study looking 
at patient experience of LVR services from referral 
through to discharge.22 Results from two focus groups 
highlighted the difficulties they faced when trying 
to access LVR centres, with patients reporting their 
‘fight’ to get a referral, one aspect of the unmet need 
which is common in respiratory disease.4 26 That 
article focused only on those patients who received 
LVR intervention and did not account for all those 
patients who were excluded from consideration for 
these important treatments because of the inequali-
ties that exist in referral pathways. Selection criteria 
should identify people who meet the criteria for LVR 
and would benefit from a procedure but who are not 
at an unacceptably high risk of a poor outcome.7 11 27 
Further research is needed to develop more system-
atic patient pathways to identify these individuals.
Routine assessment of eligibility for LVR referral 
could be considered as an opportunity to improve stan-
dards of care for all patients with COPD .19 Importantly, 
the present data do not indicate that this proportion 
of patients should be referred to a specialist centre, 
Figure 2 Flow diagram to represent patients at discharge in the 2015/2017 PR cohorts who meet the criteria to be assessed 
for a possible lung volume reduction procedure depending on criteria used. NICE criteria: FEV1 <50%, do not smoke, have 
a 6MWT of ≥140 m and have breathlessness affecting quality of life . COPD, chronic obstructive pulmonary disease; FEV1, 
forced expiratory volume in 1 s; ISWT, incremental shuttle walk test; NACAP, National Asthma and COPD Audit Programme; 
NICE, National Institute for Health and Care Excellence; PR, pulmonary rehabilitation; MRC, Medical Research Council; 6MWT, 
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but rather that every patient should be systematically 
reviewed to consider LVR referral and necessary inves-
tigations carried out to evaluate their eligibility, should 
they express an interest. Future research should focus on 
the development and refining of LVR referral pathways 
that can be practically implemented at an appropriate 
time point and setting.
CONCLUSION
Given the well- established benefits of LVR procedures 
in appropriately selected patients, these data provide 
information on the scale of activity that referral pathways 
will need to accommodate and how these are affected 
depending on the precise selection criteria used. Raising 
the potential to be considered for LVR with patients at 
the point of referral to PR may encourage programme 
adherence, thus improving health outcomes. Further-
more, linking LVR and PR pathways more formally may 
also help promote PR referral.19
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